These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 29330212)

  • 61. Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER Database.
    Hwang KT; Kim J; Jung J; Chang JH; Chai YJ; Oh SW; Oh S; Kim YA; Park SB; Hwang KR
    Clin Cancer Res; 2019 Mar; 25(6):1970-1979. PubMed ID: 30559169
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
    Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement.
    Ugras S; Stempel M; Patil S; Morrow M
    Ann Surg Oncol; 2014 Nov; 21(12):3780-6. PubMed ID: 24952028
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
    Ma H; Lu Y; Malone KE; Marchbanks PA; Deapen DM; Spirtas R; Burkman RT; Strom BL; McDonald JA; Folger SG; Simon MS; Sullivan-Halley J; Press MF; Bernstein L
    BMC Cancer; 2013 May; 13():225. PubMed ID: 23642215
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
    Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
    Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
    Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
    Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
    [TBL] [Abstract][Full Text] [Related]  

  • 68. HER2-Overexpressing Ductal Carcinoma
    O'Keefe TJ; Blair SL; Hosseini A; Harismendy O; Wallace AM
    Cancer Prev Res (Phila); 2020 Sep; 13(9):761-772. PubMed ID: 32493703
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study.
    Ran R; Zhao S; Zhou Y; Hang X; Wang H; Fan Y; Zhang Y; Qiao Y; Yang J; Dong D
    BMC Cancer; 2024 Sep; 24(1):1216. PubMed ID: 39350043
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study based on SEER database.
    Shang Y; Wang X; Liu Y; Cheng W; Duan Y; Fang Z; Liu J; Kong F; Wang T; Yu T; Hu A; Zhang J; Zhang H; Li M; Rong Z; Li Y; Shakila SS; Li X; Feng J; Ma F; Guo B
    Breast Cancer; 2024 Jul; 31(4):684-694. PubMed ID: 38643430
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status.
    Bertaut A; Mounier M; Desmoulins I; Guiu S; Beltjens F; Darut-Jouve A; Ponnelle T; Arnould L; Arveux P
    Eur J Cancer Care (Engl); 2015 Nov; 24(6):920-8. PubMed ID: 25757548
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
    Effi AB; Aman NA; Koui BS; Koffi KD; Traore ZC; Kouyate M
    Asian Pac J Cancer Prev; 2016; 17(4):1973-8. PubMed ID: 27221883
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
    He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
    Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
    Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
    J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Subtypes of Breast Cancer in Lao P.D.R.: A Study in a Limited-Resource Setting.
    Luangxay T; Virachith S; Hando K; Vilayvong S; Xaysomphet P; Arounlangsy P; Phongsavan K; Mieno MN; Honma N; Kitagawa M; Sawabe M
    Asian Pac J Cancer Prev; 2019 Feb; 20(2):589-594. PubMed ID: 30806064
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Poorer breast cancer survival outcomes in males than females might be attributable to tumor subtype.
    Wu Q; Li J; Zhu S; Wu J; Li X; Liu Q; Wei W; Sun S
    Oncotarget; 2016 Dec; 7(52):87532-87542. PubMed ID: 27655704
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs.
    Cobleigh M; Yardley DA; Brufsky AM; Rugo HS; Swain SM; Kaufman PA; Tripathy D; Hurvitz SA; O'Shaughnessy J; Mason G; Antao V; Li H; Chu L; Jahanzeb M
    Clin Cancer Res; 2020 Mar; 26(5):1105-1113. PubMed ID: 31772121
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical Characteristics and Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer in 2 Large Databases.
    Li Z; Tu Y; Wu Q; Wang Z; Li J; Zhang Y; Sun S
    Clin Breast Cancer; 2020 Apr; 20(2):e151-e163. PubMed ID: 31551181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.